Order results by:
| Issue | Title | |
| Vol 13, No 6 (2017) | PREDICTORS OF THE RISK OF HEMORRHAGIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION RECEIVING LONGTERM THERAPY WITH DIRECT ORAL ANTICOAGULANTS | Abstract similar documents |
| A. А. Sokolova, A. V. Zhilenko, I. L. Tsarev,, D. A. Napalkov, V. V. Fomin | ||
| "... and methods. 117 patients receiving DOAC (direct thrombin inhibitors – dabigatran, and Xa factor inhibitors ..." | ||
| Vol 15, No 2 (2019) | Studies of Anticoagulant Therapy in Frail Elderly Patients: Problems of Terminology and Methodology | Abstract similar documents |
| Sergey N. Bel'diev, Irina V. Medvedeva, Dmitry Yu. Platonov, Galina Yu. Trufanova | ||
| "... (ППОАК): 1) ни одно из рандомизированных контролируемых исследований (РКИ) с ППОАК (за исключение двух ..." | ||
| Vol 17, No 1 (2021) | Pharmacokinetics and Pharmacogenetics of Dabigatran | Abstract similar documents |
| A. V. Savinova, V. S. Dobrodeeva, M. M. Petrova, R. F. Nasyrova, N. A. Shnayder | ||
| "... Dabigatran etexilate is a prodrug of dabigatran, a oral direct inhibitor of thrombin ..." | ||
| Vol 18, No 3 (2022) | Clinically Significant Drug Interactions for Direct Oral Anticoagulants: State of the Art | Abstract similar documents |
| S. R. Gilyarevsky | ||
| "... the efficacy and safety of the use of direct oral anticoagulants (DOACs) in clinical practice. Data on drug ..." | ||
| Vol 15, No 2 (2019) | Studies of Anticoagulant Therapy in Frail Elderly Patients: Problems of Terminology and Methodology | Abstract similar documents |
| S. N. Bel'diev, I. V. Medvedeva, D. Yu. Platonov, G. Yu. Trufanova | ||
| "... среди других прямых пероральных антикоагулянтов (ППОАК): 1) ни одно из рандомизированных контролируемых ..." | ||
| Vol 19, No 3 (2023) | Current insights into the possible role of laboratory monitoring of effectiveness and safety of direct oral anticoagulants | Abstract similar documents |
| S. R. Gilyarevsky, N. K. Vereina, M. V. Golshmid | ||
| "... to improve the tactics of using direct oral anticoagulants (DOACs) therapy. Clinical situations in which ..." | ||
| Vol 16, No 2 (2020) | The Risk of Myocardial Infarction in Patients with Atrial Fibrillation Taking a Direct Thrombin Inhibitor: Myths and Reality | Abstract similar documents |
| B. A. Tatarsky, N. V. Kazennova, D. A. Napalkov | ||
| "... of cohort and observational studies in real clinical practice on the influence of dabigatran etexilate ..." | ||
| Vol 7, No 1 (2011) | ANTITHROMBOTIC THERAPY IN ATRIAL FIBRILLATION: NEW DATA AND NEW HORIZONS | Abstract similar documents |
| M. Yu. Gilyarov, V. A. Sulimov | ||
| "... are considered. Special attention are paid to the direct thrombin inhibitors — dabigatran. Possibilities ..." | ||
| Vol 17, No 2 (2021) | Anticoagulant Therapy in Patients with Non-valvular Atrial Fibrillation in Real Clinical Practice: in Appropriate Dose Reductions | Abstract similar documents |
| V. A. Ionin, O. I. Bliznuk, E. I. Baranova, E. V. Shlyakhto | ||
| "... Aim. To study the frequency of administration of direct oral anticoagulant (DOACs) in doses ..." | ||
| Vol 9, No 4 (2013) | COMPARATIVE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS | Abstract similar documents |
| V. A. Sulimov, D. A. Napalkov, A. A. Sokolova | ||
| "... , an oral inhibitor of Xa factor, nowadays can be considered as a drug with very good safety profile ..." | ||
| Vol 18, No 6 (2022) | Left Ventricular Thrombosis: Current Perspective and Use of Direct Oral Anticoagulants | Abstract similar documents |
| A. D. Aga, A. A. Sokolova, D. A. Napalkov | ||
| "... in direct oral anticoagulants (DOACs), the possibility of using which in LVT is being actively studied ..." | ||
| Vol 20, No 4 (2024) | Should a physician use the Beers criteria when prescribing direct oral anticoagulants to elderly patients? | Abstract similar documents |
| N. M. Vorobyeva, I. P. Malaya, V. D. Zakiev, O. N. Tkacheva | ||
| "... regarding direct oral anticoagulants (DOAC) should be treated thoughtfully and carefully. When choosing ..." | ||
| Vol 16, No 5 (2020) | The CES1 Gene rs2244613 Minor Allele Impact on the Safety Profile of Dabigatran Etexilate: Meta-Analysis | Abstract similar documents |
| S. P. Abdullaev, K. B. Mirzaev, P. O. Bochkov, I. N. Sychev, D. A. Sychev | ||
| "... influence on the equilibrium concentration and the risk of bleeding during dabigatran taking. Material ..." | ||
| Vol 8, No 6 (2012) | HOW TO USE DABIGATRAN IN PATIENTS WITH ATRIAL FIBRILLATION | Abstract similar documents |
| S. V. Moiseev | ||
| "... Dabigatran is the new oral anticoagulant that directly inhibits thrombin (factor IIa). In RE-LY ..." | ||
| Vol 9, No 5 (2013) | PRACTICAL APPLICATION OF DABIGATRAN ETEXILATE FOR STROKE PREVENTION IN PATIENTS WITH ATRIAL FIBRILLATION | Abstract similar documents |
| E. D. Kosmacheva, S. G. Kanorskiy, A. A. Kastanayan, N. V. Haylo, D. B. Goltyapin, E. A. Lipnitskaya, M. E. Statsenko | ||
| "... dabigatran etexilate, in the stroke prevention in patients with atrial fibrillation are considered. Factors ..." | ||
| Vol 12, No 5 (2016) | Dabigatran Etexilate in the course of Electrical Cardioversion in Patients with Non-Valvular Atrial Fibrillation | Abstract similar documents |
| N. A. Novikova, A. N. Volovchenko | ||
| "... events in patients with AF. Possibility to perform planned cardioversion while receiving dabigatran has ..." | ||
| Vol 18, No 5 (2022) | Thrombocytopenia Induced by Direct Oral Anticoagulants: a Clinical Case and Literature Review | Abstract similar documents |
| B. A. Tatarsky, N. V. Kazennova | ||
| "... thrombin blockers (dabigatran) or factor IIa blockers (apixaban, rivaroxaban, edoxaban). According ..." | ||
| Vol 13, No 5 (2017) | DRUG INTERACTIONS OF NEW ORAL ANTICOAGULANTS: INSIDE AND OUTSIDE TABLE CELLS | Abstract similar documents |
| S. N. Bel'diev, I. V. Medvedeva, D. Yu. Platonov | ||
| Vol 7, No 6 (2011) | DABIGATRAN ETEXILATE FOR PREVENTION OF CARDIOEMBOLIC COMPLICATIONS IN NONVALVULAR ATRIAL FIBRILLATION: HOW TO DO THE INTERVENTION MORE EFFECTIVE AND SAFER | Abstract similar documents |
| I. S. Yavelov | ||
| "... Application of dabigatran etexilate for prevention of cardioembolic complications in nonvalvular ..." | ||
| Vol 13, No 5 (2017) | Drug interactions of non-vitamin K antagonist oral anticoagulants: inside and outside table cells | Abstract similar documents |
| Sergey Nikolaevich Bel'diev, Irina Vladimirovna Medvedeva, Dmitry Jur'evich Platonov | ||
| Vol 9, No 2 (2013) | ERA OF NEW ANTICOAGULANTS IN THE TREATMENT OF NON-VALVULAR ATRIAL FIBRILLATION: PROSPECTS AND CHALLENGES | Abstract similar documents |
| Z. M. Safiullina, S. V. Shalaev | ||
| "... Studies data on new anticoagulants, direct oral thrombin inhibitor (dabigatran) and direct ..." | ||
| Vol 17, No 4 (2021) | Effect of Direct Oral Anticoagulants for Ulcer Epithelization and Laser Doppler Flowmetry Parameters In Patients with Diabetic Foot Syndrome and Atrial Fibrillation | Abstract similar documents |
| V. I. Petrov, N. V. Rogova, T. N. Кuzmina, A. S. Lishuta | ||
| "... therapy with the addition of DOACs (rivaroxaban and dabigatran). Further research for DOACs in DFS ..." | ||
| Vol 17, No 2 (2021) | Dynamics of Kidney Function in Patients with Chronic Kidney Disease and Atrial Fibrillation Who Receive Dabigatran | Abstract PDF (Eng) similar documents |
| N. A. Novikova, Z. K. Salpagarova, M. I. Chashkina, A. A. Bykova, Z. A. Alimova, А. S. Yadykina, D. F. Mesitskaya, N. A. Babakova, D. A. Andreev | ||
| "... of the anticoagulant therapy in the outpatient practice. Initially, 133 dabigatran taking patients were enrolled ..." | ||
| Vol 12, No 2 (2016) | THE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION IN CLINICAL PRACTICE | Abstract similar documents |
| S. V. Moiseev | ||
| "... (dabigatran), today are increasingly replacing warfarin and other indirect anticoagulants in preventing stroke ..." | ||
| Vol 12, No 4 (2016) | Clinical significance of new oral anticoagulants in the prevention of thromboembolic complications in patients with atrial fibrillation: not all dreams come true | Abstract similar documents |
| Yu. A. Bunin, S. V. Miklishanskaya | ||
| Vol 13, No 1 (2017) | DATA OF CLINICAL PRACTICE AS A TOOL FOR CHOICE OF DIRECT ORAL ANTICOAGULANT | Abstract similar documents |
| D. А. Napalkov, A. A. Sokolova, V. V. Fomin | ||
| Vol 13, No 3 (2017) | PHARMACOGENETIC ASPECTS OF NEW ORAL ANTICOAGULANTS APPLICATION | Abstract similar documents |
| A. V. Kryukov, D. A. Sychev, O. V. Tereshchenko | ||
| "... on the pharmacokinetics of these drugs. RE-LY study showed a 15% decrease in trough dabigatran concentration and 27% lower ..." | ||
| Vol 7, No 5 (2011) | ANTITHROMBOTIC THERAPY IN ATRIAL FIBRILLATION: RECENT APPROACHES AND NEAR PERSPECTIVES | Abstract similar documents |
| Ya. P. Dovgalevskiy, L. E. Kuvshinova, I. V. Graifer, N. V. Furman, P. Ya. Dovgalevskiy | ||
| Vol 9, No 3 (2013) | ANTICOAGULANT THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION: DRUG CHOICE AND DOSAGE ADJUSTMENT | Abstract similar documents |
| E. L. Dolgova, I. M. Sokolov, Yu. G. Shvarts | ||
| Vol 11, No 3 (2015) | ANALYSIS OF THE INFLUENCE OF THROMBOEMBOLIC COMPLICATIONS PREVENTION WITH ORAL ANTICOAGULANTS ON BUDGET IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION | Abstract similar documents |
| A. V. Rudakova | ||
| "... administration of vitamin K antagonists (warfarin) or the new oral anticoagulants (apixaban, dabigatran ..." | ||
| Vol 9, No 4 (2013) | COMPARISON OF DIRECT COSTS OF DABIGATRAN AND WARFARIN THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION DURING PREPARATION FOR ELECTIVE CARDIOVERSION IN THE REAL CLINICAL PRACTICE | Abstract similar documents |
| L. E. Kuvshinova, N. V. Furman, P. V. Dolotovskaya, Ya. P. Dovgalevsky | ||
| "... Aim. To compare direct medical costs of dabigatran and warfarin therapy in patients with non ..." | ||
| Vol 10, No 4 (2014) | NEW ORAL ANTICOAGULANTS: FOCUS ON THE SAFETY | Abstract similar documents |
| D. A. Napalkov, A. A. Sokolova | ||
| "... dabigatran, rivaroxaban and apixaban) is presented from the standpoint of safety. The safety profile ..." | ||
| Vol 16, No 1 (2020) | Control Of Anticoagulation Therapy in Atrial Fibrillation (COAT-AF Study) in Real Clinical Practice | Abstract similar documents |
| A. A. Zarudsky, A. A. Gavrilova, Т. S. Filinichenko | ||
| Vol 16, No 5 (2020) | New Pharmacogenetic Markers to Predict the Risk of Bleeding During Taking of Direct Oral Anticoagulants | Abstract PDF (Eng) similar documents |
| K. B. Mirzaev, D. V. Ivashchenko, I. V. Volodin, E. A. Grishina, K. A. Akmalova, A. A. Kachanova, A. I. Skripka, R. M. Minnigulov, T. E. Morozova, O. A. Baturina, A. N. Levanov, T. V. Shelekhova, A. I. Kalinkin, D. A. Napalkov, A. A. Sokolova, D. A. Andreev, I. N. Sychev, P. O. Bochkov, D. A. Sychev | ||
| "... and dabigatran for different indications: atrial fibrillation, endoprosthesis of large joints of lower limbs ..." | ||
| Vol 17, No 1 (2021) | Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Renal Dysfunction | Abstract similar documents |
| Z. D. Kobalava, A. A. Shavarov, M. V. Vatsik-Gorodetskaya | ||
| Vol 15, No 5 (2019) | Rivaroxaban-Associated Hepatotoxicity: a Clinical Case and Literature Review | Abstract similar documents |
| B. A. Tatarsky, N. V. Kazennova, D. A. Napalkov | ||
| Vol 8, No 1 (2012) | PHARMACOECONOMIC EVALUATION OF DABIGATRAN VS WARFARIN IN CARDIOVASCULAR EVENTS PREVENTION IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION | Abstract similar documents |
| Yu. B. Belousov, V. Yu. Mareev, I. S. Yavelov, D. Yu. Belousov | ||
| "... According to recent guidelines, oral dabigatran etexilate is indicated for stroke and systemic ..." | ||
| Vol 18, No 6 (2022) | Effect of ABCB1 Gene Carriage and Drug-Drug Interactions on Apixaban and Rivaroxaban Pharmacokinetics and Clinical Outcomes in Patients with Atrial Fibrillation and Deep Vein Thrombosis | Abstract similar documents |
| L. V. Fedina, I. N. Sychev, T. D. Rastvorova, E. V. Strigunkova, A. A. Kachanova, Z. A. Sozaeva, P. O. Bochkov, A. V. Vardanyan, K. B. Mirzayev, D. A. Sychev | ||
| "... apixaban together with a CYP3A4/P-gp inhibitor were 3.5 times more likely to have hemorrhagic complications ..." | ||
| Vol 11, No 1 (2015) | PHARMACOECONOMIC ASPECTS OF APIXABAN FOR PREVENTION OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION | Abstract similar documents |
| A. V. Rudakova | ||
| "... , rivaroxaban and dabigatran. Along with clinical efficacy and safety profile one of the main characteristics ..." | ||
| Vol 15, No 6 (2019) | Safety of Non-Vitamin K Oral Anticoagulants in Elderly Patients with Atrial Fibrillation | Abstract similar documents |
| M. A. Gabitova, P. M. Krupenin, A. A. Sokolova, D. A. Napalkov, V. V. Fomin | ||
| "... of age with confirmed AF, receiving dabigatran in a reduced dosage, apixaban or rivaroxaban in full ..." | ||
| Vol 16, No 1 (2020) | The Efficacy, Safety and Adherence to Treatment when New Anticoagulants Taking in Over 75 Years Old Patients with Atrial Fibrillation | Abstract similar documents |
| A. N. Turov, S. V. Panfilov, О. V. Tschiglinzeva | ||
| "... of the observation study was from 12 to 42 (26.9±4.9) months. Dabigatran was taken in 38.5% (n=166) of patients ..." | ||
| Vol 9, No 5 (2013) | APPLICATIONS OF PHARMACOGENETIC TESTING FOR PERSONALIZATION OF THERAPY WITH ORAL ANTICOAGULANTS IN RUSSIA | Abstract similar documents |
| D. A. Sychev, R. E. Kazakov, V. A. Otdelenov, A. B. Prokofiev | ||
| Vol 14, No 3 (2018) | THROMBOSIS OF LEFT ATRIAL APPENDAGE DURING THERAPY WITH DIRECT ORAL ANTICOAGULANT. CLINICAL CASE | Abstract similar documents |
| I. S. Daaboul, S. Yu. Koroleva, A. A. Kudrjavtseva, A. A. Sokolova, D. A. Napalkov, V. V. Fomin | ||
| "... , it was decided to replace apixaban with another direct oral anticoagulant – dabigatran 150 mg bid for a period ..." | ||
| Vol 14, No 4 (2018) | Hepatotoxicity of New Oral Anticoagulants | Abstract similar documents |
| A. R. Kasimova, A. V. Philippova (Guryanova), A. S. Kolbin | ||
| Vol 16, No 6 (2020) | An Elderly Comorbid Patient with Atrial Fibrillation: What is Important to Know and What Should be Considered When Prescribing Anticoagulants? | Abstract similar documents |
| T. V. Pavlova | ||
| Vol 12, No 5 (2016) | Features of Modern Anticoagulant Therapy in Patients with Nonvalvular Atrial Fibrillation and Chronic Kidney Disease | Abstract similar documents |
| I. S. Daabul, A. A. Sokolova, D. A. Napalkov | ||
| Vol 17, No 5 (2021) | Gastrointestinal Bleeding: a Cardiologist's Point of View | Abstract similar documents |
| O. V. Averkov, L. N. Mishchenko | ||
| "... antagonists (warfarin) as well as direct oral anticoagulants (DOAC): dabigatran, rivaroxaban, apixaban ..." | ||
| Vol 9, No 6 (2013) | THE ROLE OF P-GLYCOPROTEIN IN RATIONAL PHARMACOTHERAPY IN CARDIOLOGY | Abstract similar documents |
| A. V. Shulkin, E. N. Yakusheva, N. M. Popova | ||
| "... , prasugrel) and anticoagulants (dabigatran etexilate, rivaroxaban, edoxaban) is not feasible in routine ..." | ||
| Vol 17, No 5 (2021) | Efficiency of the Left Atrial Appendage Thrombus Dissolution in Patients with Persistent Nonvalvular Atrial Fibrillation with Warfarin or Direct Oral Anticoagulants Therapy | Abstract PDF (Eng) similar documents |
| E. S. Mazur, V. V. Mazur, N. D. Bazhenov, Yu. A. Orlov | ||
| "... with persistent nonvalvular atrial fibrillation receiving warfarin and direct oral anticoagulants (DOAC ..." | ||
| Vol 14, No 6 (2018) | Specific Antidotes for Direct Oral Anticoagulants in Life-Threatening Bleeding | Abstract PDF (Eng) similar documents |
| A. B. Sumarokov, L. I. Buryachkovskaya, N. V. Lomakin | ||
| "... anticoagulants (DOACs) inhibitors, as antidotes for DOAC when stopping life-threatening bleeding. DOAC therapy ..." | ||
| Vol 21, No 2 (2025) | Anticoagulant therapy in patients with cardioembolic subtype of ischemic stroke and atrial fibrillation | Abstract similar documents |
| E. A. Naryshkina, M. I. Chashkina, E. S. Zadykyan, N. K. Kurbanalieva, E. M. Zakaryan, M. V. Serova, D. A. Andreev, A. G. Komarova, K. E. Eroshkin, A. A. Kulesh, D. A. Sychev | ||
| "... on outpatient ACT were included; rivaroxaban (n=56), apixaban (n=30), dabigatran etexilate (n=11), and warfarin ..." | ||
| Vol 19, No 5 (2023) | Inhospital outcomes of myocardial infarction in patients receiving direct oral anticoagulants | Abstract similar documents |
| M. G. Chashchin, A. Yu. Gorshkov, O. M. Drapkina | ||
| "... ) in patients receiving continuous direct oral anticoagulant (DOAC) therapy. Material and methods. Data from ..." | ||
| Vol 20, No 4 (2024) | Nephroprotective and anticoagulant therapy in patients with atrial fibrillation and chronic kidney disease: real-world data | Abstract similar documents |
| A. I. Listratov, I. I. Ivanov, N. K. Ziskina, V. V. Efimenko, A. V. Zhavoronkova, E. S. Milyakova, A. A. Kudrjavtseva, D. A. Napalkov, A. A. Sokolova | ||
| "... characteristics were retrospectively assessed, as were the use of renin-angiotensin system inhibitors (RASi ..." | ||
| Vol 10, No 2 (2014) | SECONDARY PREVENTION OF STROKE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION: THE CLINICIANS’ VIEWPOINT | Abstract similar documents |
| E. A. Drozdova | ||
| "... assessment of warfarin and dabigatran therapies is given. ..." | ||
| Vol 16, No 1 (2020) | Clinical Significance of Thrombin Blockade with Low Doses (2.5 mg) of Rivaroxaban in Ischemic Heart Disease Patients | Abstract similar documents |
| A. B. Sumarokov, L. I. Buryachkovskaya, Y. V. Docenko, M. S. Kurochkin, N. V. Lomakin | ||
| "... in this process. Low doses of direct oral inhibitors of thrombin are able to potentiate antithrombotic effect ..." | ||
| Vol 11, No 3 (2015) | PHARMACOECONOMIC ASPECTS OF THE PREVENTION OF VENOUS THROMBOEMBOLIC EVENTS AFTER LARGE JOINTS REPLACEMENT | Abstract similar documents |
| A. V. Rudakova | ||
| "... average prices of public bidding for the purchase of drugs (enoxaparin, dabigatran and apixaban) during ..." | ||
| Vol 20, No 5 (2024) | Effectiveness and safety of direct oral anticoagulants in patients with atrial fibrillation and chronic kidney disease: a systematic review and meta-analysis of clinical trials | Abstract similar documents |
| E. M. Mezhonov, Z. M. Safiullina, Y. A. Vyalkina, S. V. Shalaev | ||
| "... oral anticoagulants" or "direct oral anticoagulants" or "novel oral anticoagulant" or "NOAC" or "DOAC ..." | ||
| Vol 11, No 2 (2015) | ANTICOAGULANT THERAPY IN EVERYDAY CLINICAL PRACTICE: DATA OF THE RETROSPECTIVE CROSS-SECTIONAL STUDY | Abstract PDF (Eng) similar documents |
| V. A. Sulimov, D. A. Napalkov, A. A. Sokolova, A. V. Jilenko, O. S. Anikina | ||
| "... % of the patients received novel oral anticoagulants (dabigatran – 14%, rivaroxaban – 2%). Bleeding was fixed in 4 ..." | ||
| Vol 16, No 6 (2020) | The Oral Anticoagulants Administration in Elderly Patients with Geriatric Syndromes: What's New? | Abstract similar documents |
| N. M. Vorobyeva, O. N. Tkacheva | ||
| "... is presented. Most studies indicate significant advantages of direct oral anticoagulants (dabigatran ..." | ||
| Vol 17, No 4 (2021) | Antithrombotic Management for Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention | Abstract similar documents |
| A. V. Panov | ||
| "... inhibitors and direct oral anticoagulant (DOAC) instead of vitamin K antagonists. The primary choice of DOAC ..." | ||
| Vol 19, No 6 (2023) | Acute kidney injury as a risk factor for atrial fibrillation after coronary artery bypass grafting — effects of sodium-glucose cotransporter-2 inhibitors | Abstract similar documents |
| L. V. Kremneva, L. A. Arutyunyan, L. I. Gapon, S. N. Suplotov, S. V. Shalaev | ||
| "... cotransporter 2 (SGLT-2) inhibitors. Material and methods. We examined 92 patients with stable angina who ..." | ||
| Vol 18, No 1 (2022) | Modern Anticoagulant Therapy for Atrial Fibrillation: Patient Adherence in Clinical Practice | Abstract similar documents |
| Yu. P. Skirdenko, N. A. Nikolaev, K. G. Pereverzeva, A. Yu. Timakova, A. S. Galus, S. S. Yakushin | ||
| "... .6%) and dabigatran (17.3%) and warfarin (19.4%) were prescribed almost twice as rarely as rivaroxaban ..." | ||
| Vol 6, No 1 (2010) | SOME ASPECTS OF THE LISINOPRIL USAGE IN ARTERIAL HYPERTENSION TREATMENT | Abstract similar documents |
| N. A. Jaiani | ||
| Vol 7, No 1 (2011) | NEW ANTIPLATELET DRUGS (PART 1) | Abstract similar documents |
| A. B. Sumarokov | ||
| "... antiplatelet drugs are on their way to clinical application — prasugrel, ticagrelor, elinogrel, inhibitors ..." | ||
| Vol 10, No 5 (2014) | CHOICE OF LISINOPRIL FOR TREATMENT OF HYPERTENSION IN PATIENTS WITH CONCOMITANT DISEASES | Abstract similar documents |
| N. A. Dzhaiani | ||
| "... Rationale and benefits of the use of the ACE inhibitor lisinopril in the clinical practice ..." | ||
| Vol 5, No 1 (2009) | ACE INHIBITORS IN ARTERIAL HYPERTENSION TREATMENT: FOCUS ON LISINOPRIL | Abstract similar documents |
| V. I. Podzolkov, K. K. Osadchy | ||
| "... inhibitor lisinopril is surveyed. Data about lisinopril effects on different endpoints, organoprotective ..." | ||
| Vol 19, No 1 (2023) | Analysis of The Use of PCSK9 Inhibitors in Clinical Practice | Abstract similar documents |
| S. Yu. Volkova, L. A. Boyarskaya, P. Yu. Toropygin, I. A. Morozov, E. A. Boyarskaya | ||
| "... Aim. The analysis of the experience of using PCSK9 inhibitors (alirocumab) in patients with very ..." | ||
| Vol 4, No 2 (2008) | ACE INHIBITORS ARE RATIONAL PHARMACOTHERAPY OF ENDOTHELIAL DYSFUNCTION | Abstract similar documents |
| M. P. Metrova, A. B. Salmina, A. I. Inzhutova, O. S. Bahmeteva | ||
| "... Aim. To study effects of ACE inhibitor perindopril on markers of endothelial dysfunction ..." | ||
| Vol 13, No 5 (2017) | WARFARIN AND ITS IMPORTANCE IN THE ERA OF NEW ORAL ANTICOAGULANTS. ISSUES OF MONITORING THE EFFECTIVENESS AND SAFETY OF TREATMENT | Abstract similar documents |
| S. Yu. Martsevich, Y. V. Lukina | ||
| "... of new OAC (NOAC) also appeared. In Russia, dabigatran, rivaroxaban and apixaban have been registered ..." | ||
| Vol 7, No 5 (2011) | NEW ANTIPLATELET DRUGS. PART 2 | Abstract similar documents |
| A. B. Sumarokov | ||
| "... are on their way to clinical application — prasugrel, ticagrelor , elinogrel, thromboxane receptor inhibitors ..." | ||
| Vol 10, No 3 (2014) | COST-EFFECTIVENESS OF APIXABAN AS COMPARED WITH WARFARIN AND ACETYLSALICYLIC ACID IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN THE RUSSIAN FEDERATION | Abstract similar documents |
| A. V. Rudakova, V. A. Parfenov | ||
| "... anticoagulants such as apixaban, rivaroxaban and dabigatran. Administration of vitamin K antagonists (VKA ..." | ||
| Vol 5, No 3 (2009) | ANGIOTENSIN CONVERTING ENZYME INHIBITORS IN MANAGEMENT OF PATIENTS WITH CHRONIC HEART FAILURE | Abstract similar documents |
| S. N. Tereshchenko, N. A. Dzhaiani | ||
| "... The role of ACE inhibitors in modern pharmacotherapy of patients with chronic heart failure (CHF ..." | ||
| Vol 6, No 5 (2010) | PHOSPHODIESTERASE-5 INHIBITORS USE IN PATIENTS WITH ERECTILE DYSFUNCTION AND CARDIOVASCULAR DISEASE IN CLINICAL PRACTICE | Abstract similar documents |
| M. N. Mamedov, G. G. Sharvadze, E. A. Poddubsky, A. K. Ausheva | ||
| "... . The phosphodiesterase-5 (PDE5) inhibitors increase the relaxing effect of nitric oxide and increase cyclic GMP levels ..." | ||
| Vol 10, No 6 (2014) | СONCOMITANT ADMINISTRATION OF CLOPIDOGREL AND PROTON PUMP INHIBITORS: ARE THERE ANY OPEN QUESTIONS LEFT TODAY? | Abstract similar documents |
| S. Yu. Martsevich, A. Yu. Suvorov | ||
| "... Concomitant administration of clopidogrel and proton pump inhibitors (PPI), the possible influence ..." | ||
| Vol 1, No 1 (2005) | ACE INHIBITORS IN PATIENTS WITH ISCHEMIC HEART DISEASE WITHOUT HEART FAILURE: CLASS EFFECTS AND EFFICACY OF ITS REPRESENTATIVES | Abstract similar documents |
| Y. A. Karpov | ||
| "... of the role of ACE inhibitors in treatment of patients with stable form of ischemic heart disease without ..." | ||
| Vol 8, No 4 (2012) | EFFECT OF CARDIOVASCULAR DRUGS ON BONE HEALTH AND THE POSSIBILITY OF THEIR USE FOR THE PREVENTION OF OSTEOPOROSIS | Abstract similar documents |
| I. A. Skripnikova, K. E. Sobchenko, O, V. Kosmatova, D. V. Nebieridze | ||
| "... and, first of all beta-blockers, ACE inhibitors, diuretics, and statins on bone are presented. Mode of action ..." | ||
| Vol 4, No 3 (2008) | COMPARATIVE EFFICACY OF ACE INHIBITORS (RAMIPRIL VS ENALAPRIL) IN TREATMENT OF CHRONIC HEART FAILURE IN WOMEN | Abstract similar documents |
| S. N. Tereshchenko, I. V. Zhirov, E. V. Malichenko, E. E. Kazantseva | ||
| Vol 4, No 3 (2008) | ANGIOTENSIN II AND MYOCARDIAL INFARCTION | Abstract similar documents |
| O. P. Shevchenko, А. О. Shevchenko | ||
| "... ) inhibitors reduce mortality and improve prognosis of patients with acute MI. In patients with ischemic heart ..." | ||
| Vol 5, No 2 (2009) | CARDIOPROTECTIVE AND NEPHROPROTECTIVE EFFECTS OF ANGIOTENSIN CONVERTING ENZYME INHIBITOR RAMIPRIL | Abstract similar documents |
| D. A. Napalkov, E. N. Golovenko | ||
| "... There is grate interest to ACE inhibitors which have cardioprotective and neproprotective effects ..." | ||
| Vol 6, No 4 (2010) | ACE INHIBITOR POSSIBILITIES IN CLINICAL PRACTICE: WHAT WE KNOW ABOUT THEM? | Abstract similar documents |
| D. V. Nebieridze, A. S. Safarian | ||
| "... New possibilities of ACE inhibitors application on the base of international trails review ..." | ||
| Vol 1, No 1 (2005) | EXPERT CONSENSUS DOCUMENT ON ANGIOTENSIN CONVERTING ENZYME INHIBITORS IN CARDIOVASCULAR DISEASE | Abstract similar documents |
| Jose Lopez-Sendon, Karl Swedberg, John McMurray, Juan Tamargo, Aldo P. Maggioni, Henry Dargie, Michal Tendera, Finn Waagstein, Jan Kjekshus, Philippe Lechat, Christian Torp-Pedersen | ||
| "... Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. ..." | ||
| Vol 3, No 1 (2007) | THE CAPABILITIES OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS IN CLINICAL PRACTICE: FOCUS ON VASOPROTECTION | Abstract similar documents |
| D. B. Nebieridze, A. S. Safaryan | ||
| "... enzyme (ACE) inhibitors in clinical practice were represented. The traditional usage of ACE eminhibitors/em ..." | ||
| Vol 8, No 2 (2012) | RESIDUAL PLATELET REACTIVITY DURING THERAPY WITH INHIBITORS OF CYCLOOXIGENASE OR ADENOSINE DIPHOSPHATE RECEPTORS | Abstract similar documents |
| A. A. Lomonosova, N. A. Mazur, E. A. Zolozova, E. V. Sayutina, V. V. Chigineva, N. V. Shestakova | ||
| Vol 16, No 4 (2020) | Inhibitors in the Management of Patients with Atherosclerotic Cardiovascular Diseases: Guidelines and Reimbursement Issues | Abstract similar documents |
| M. V. Zhuravleva, A. B. Prokofiev, E. V. Shikh, S. Yu. Serebrova, G. I. Gorodetskaya, E. Yu. Demchenkova | ||
| "... considers the place of proprotein convertase subtilisin/kexin type 9 (PCSK9) eminhibitors/em in the prevention ..." | ||
| Vol 17, No 6 (2021) | PCSK9 Inhibitors in Clinical Practice: Experience of a Specialized Lipid Center | Abstract similar documents |
| A. V. Blokhina, A. I. Ershova, A. S. Limonova, O. V. Kopylova, A. N. Meshkov, O. M. Drapkina | ||
| "... Aim. To characterize patients receiving PCSK9 eminhibitors/em, and assess the efficiency ..." | ||
| Vol 20, No 2 (2024) | Cardiotoxicity mechanisms of antitumor therapy with immune checkpoint inhibitors: new achievements | Abstract similar documents |
| L. D. Khidirova, A. E. Latsvieva, A. V. Vederin | ||
| "... The immune checkpoint eminhibitors/em (ICTs) emergence has opened up new perspectives in cancer ..." | ||
| Vol 15, No 6 (2019) | Adherence to Treatment with New Oral Anticoagulants in Atrial Fibrillation Patients in Real Clinical Practice (Results of the ANTEY Study) | Abstract similar documents |
| S. Yu. Martsevich, Yu. V. Lukina, N. P. Kutishenko, S. N. Tolpygina, V. P. Voronina, N. A. Dmitrieva, O. V. Lerman, N. A. Komkova | ||
| "... recommended the use of rivaroxaban; 47 (23.4%) – the use of emdabigatran/em and 43 (21.4%) – the use of apixaban ..." | ||
| Vol 14, No 2 (2018) | NEW DIRECT ORAL ANTICOAGULANTS FOR TREATMENT OF PATIENTS WITH ATRIAL FIBRILLATION IN REAL-WORLD SETTING | Abstract similar documents |
| Zh. D. Kobalava, S. V. Villevalde, A. A. Shavarov | ||
| "... ) showed that new direct oral anticoagulants (emDOACs/em) were just as effective at preventing stroke ..." | ||
| Vol 16, No 2 (2020) | Algorithm for the Choice of Anticoagulant for Patients with Atrial Fibrillation | Abstract similar documents |
| Yu. P. Skirdenko, N. A. Nikolaev | ||
| "... anticoagulants (emDOACs/em) (χ2=1.44; p0.49, Pearson) and significantly more in individuals taking warfarin ..." | ||
| Vol 5, No 4 (2009) | TO THE 110-TH ANNIVERSARY OF RENIN FINDING. FIGHT OF TITANS: ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND SARTANS | Abstract similar documents |
| L. N. Malay, A. N. Miroshnichenko, B. V. Sharykin, V. V. Konurovsky | ||
| "... Angiotensin converting enzyme (ACE) eminhibitors/em and angiotensin II receptor blockers (ARB) slow ..." | ||
| Vol 7, No 1 (2011) | SUPPRESSION OF RENIN-ANGIOTENSIN SYSTEM TO PREVENT COMPLICATIONS OF CARDIOVASCULAR DISEASES: CURRENT "ROLES" DISTRIBUTION FROM CLINICAL PHARMACOLOGIST’S POINT OF VIEW | Abstract similar documents |
| S. R. Gilyarevskiy, V. A. Orlov, M. V. Golshmid, G. Yu. Zakharova, I. I. Sinitsina | ||
| "... A role of angiotensin-converting enzyme (ACE) eminhibitors/em in cardiovascular diseases treatment ..." | ||
| Vol 6, No 1 (2010) | ANGIOTENSIN II RECEPTOR ANTAGONISTS AND ACE INHIBITORS: OPTIMIZATION OF CHOICE FOR TREATMENT OF CARDIOVASCULAR DISEASES | Abstract similar documents |
| E. M. Khurs, A. V. Poddubnaya | ||
| "... Aim. To evaluate the cardioprotective effects of ACE eminhibitor/em, ramipril and angiotensin II ..." | ||
| Vol 6, No 1 (2010) | COMBINED ANTIHYPERTENSIVE THERAPY: ACE INHIBITOR PLUS CALCIUM CHANNEL BLOCKER. NEW ADVANTAGES OF THE KNOWN COMBINATION | Abstract similar documents |
| S. A. Boitsov, R. M. Linchak | ||
| "... attention is paid to usage of ACE eminhibitor/em and calcium antagonist combination. ..." | ||
| Vol 13, No 2 (2017) | SECONDARY PREVENTION IN PATIENTS AFTER MYOCARDIAL INFARCTION AT AMBULATORY SPECIALIZED CARDIOLOGY INSTITUTION (PHARMACOEPIDEMIOLOGY STUDY) | Abstract similar documents |
| S. B. Fitilev, I. I. Shkrebneva, A. V. Vozzhaev, D. A. Dimitrova | ||
| Vol 14, No 1 (2018) | COMORBID PATIENT IN GASTROENTEROLOGY: INDIVIDUAL APPROACH | Abstract similar documents |
| I. G. Bakulin, S. A. Sayganov, M. I. Skalinskaya, E. V. Skazyayeva, I. V. Lapinskii | ||
| "... eminhibitors/em, depending on clinical dynamics. The rationale for the replacement of proton pump eminhibitors/em ..." | ||
| Vol 6, No 5 (2010) | THE USE OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS AFTER MYOCARDIAL INFARCTION. WHAT DO EVIDENCE-BASED MEDICINE DATA SPEAK FOR? | Abstract similar documents |
| S. Yu. Martsevich | ||
| "... The main trails proven angiotensin converting enzyme (ACE) eminhibitor/em effects on the life prognosis ..." | ||
| Vol 6, No 5 (2010) | NEW APPROACHES OF THE HYPERTENSION TREATMENT: FROM CHOOSING THE BEST DRUG TO CHOOSE THE OPTIMUM DRUGS COMBINATION | Abstract similar documents |
| O. D. Ostroumova, E. A. Smolyarchuk, I. V. Khvorostyanaya | ||
| "... are presented. The advantages of ACE eminhibitor/em+calcium channel blocker combination are shown in terms ..." | ||
| Vol 9, No 4 (2013) | ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS: IS THERE A REASON TO CONSIDER AN EQUIVALENCE OF TWO DRUG CLASSES FROM THE EVIDENCE BASED MEDICINE STANDPOINT | Abstract similar documents |
| S. Yu. Martsevich | ||
| "... The results of the main large controlled trials that had proven effect of ACE eminhibitors/em (ACEi ..." | ||
| Vol 16, No 2 (2020) | Treatment of Patients with COVID-19 and Concomitant Cardiovascular Diseases: Do not Forget About the Principles of Evidence-based Medicine | Abstract similar documents |
| S. Yu. Martsevich | ||
| "... The recent discussion about the dangers of using angiotensin-converting-enzyme (ACE) eminhibitors/em ..." | ||
| Vol 3, No 2 (2007) | RESULTS OF OUTPATIENT PROGRAM ON EFFECTIVE THERAPY OF REFRACTORY ARTERIAL HYPERTENSION | Abstract similar documents |
| M. M. Batyushin, I. V. Derevyankina, M. Z. Gasanov, O. V. Akopova, K. I. Babiyan, Y. N. Boychenko, N. V. Vasilchenko, T. A. Gabysyan, S. Ch. Gayboryan, I. S. Golovatenko, N. M. Demkova, D. O. Dmitriev, E. V. Kirtava, O. L. Kotyankova, G. V. Ludanova, S. A. Lyashenko, A. E. Malichina, O. I. Poroshenko, A. V. Svechnikova, I. Y. Sidorov, E. V. Solyannikova, I. D. Tascheyan, E. A. Heygetyan, S. E. Evruyan | ||
| "... converting enzyme (ACE) eminhibitor/em, thiazid diuretic (indapamide) and dihydropyridine calcium antagonist ..." | ||
| 1 - 100 of 328 Items | 1 2 3 4 > >> | |
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)
